"In a call with analysts,Buffalo Wild Wings CEO Sally Smith said chicken wing costs were 26 percent higher than a year ago and the company spent more on labor due to higher wages and the company's new "guest experience captain" position. To compensate, the chain will boost prices on alcohol in August and other items this fall,"
Looks like this Hollins hump is eating fewer wings these days and paying more for his beer at Buffalo Wild Wings. Stock up big today as investors realize guys like that will continue to blow their paychecks on higher priced wings & beer.
July 28, 2015 /PRNewswire/ -- "Cepheid (CPHD) and FIND today unveiled the GeneXpert® Omni, the world's most portable molecular diagnostics system enabling unprecedented access to accurate, fast and potentially life-saving diagnosis for patients suspected of TB, HIV and Ebola in even the most remote areas of the world.
At just 9 inches tall (about 23 cm) and weighing just 2.2 pounds (about 1kg), the GeneXpert Omni will run the same high quality PCR-based cartridge tests as Cepheid's existing family of GeneXpert Systems. Additionally, the GeneXpert Omni is battery-operated, wireless and web-enabled, setting a new standard in connectivity to transmit instrument and test information in real-time. The GeneXpert Omni is expected to substantially extend the reach of Cepheid's industry-leading technology platform, enabling true point-of-care testing for life-threatening conditions, including tuberculosis, drug-resistant tuberculosis, HIV and Ebola, to be conducted on demand at the patient's location.
"For too long, access to best-in-class molecular diagnostics has been limited by the complexity of the tests and the systems that run them," said John Bishop, Cepheid's Chairman and Chief Executive Officer. "With the GeneXpert Omni, global accessibility to molecular diagnostics is possible for the first time. The system's unprecedented portability means that it can literally go anywhere, and deliver critical diagnostic test results to support disease determination, treatment, and improved patient outcomes."
This appears to be a game-changer in the field of molecular diagnostics.
June 30, 2015 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc., announced today its declaration of conformity to the European In Vitro Diagnostic Directive 98/79 EC and CE Mark of the Accelerate ID/AST System and ID/AST Blood Culture Assay for in vitro diagnostic use. The Accelerate ID/AST System is a diagnostic platform providing rapid identification and antimicrobial susceptibility testing of serious infections.
In addition, the company initiated enrollment at 8 clinical trial sites for its preclinical study. Upon successful completion the FDA registration trial will begin. Given the aforementioned progress, the company maintains its expectation that it will launch an FDA cleared product in the United States in the first half of 2016."
Stay current Zag,....why concern yourself with something from 15 years ago having no bearing on current technology. Ya follow?
So your point being it is enlightening to look at a 5 year stock chart comparison of AXDX versus NNLX?
"NanoLogix recently received a substantial royalty payment for 2008 from NutraPharma, a bio-pharmaceutical company with a license on a number of NanoLogix patents.
From NutraPharma licensing agreement of 2006.
4.2 Licensee shall pay to Licensor a Minimum Royalty Fee of $20,000 in the first calendar year, $20,000 in the second calendar year, $40,000 in the third calendar year, $80,000 in the fourth calendar year, and $160,000 in each calendar year after that, through the termination of this Agreement. (this is year 3, $40,000 due)"
There is the sales royalty arrangement for the mycobacteria slide detection kits with Nutrapharma .
Parents 6 years ago--"Do not be concerned. Bret Barnhizer's entire professional life has been in energy. He KNOWS the value of developing the energy sector. Bret originally invested in NNLX because of the potential for the development of inexpensive hydrogen energy"
So Zag, Parents seems to think Barnhizer was a big fan of what you proclaimed to be the "hydrogen nonsense."
"Corgenix Medical Corporation, the U.S. based operation of ORGENTEC Diagnostika, is presenting several scientific abstracts at the 2015 American Association for Clinical Chemistry (AACC) Clinical Lab Expo in Atlanta.
On July 28 in the AACC Clinical Studies/Outcomes session, Corgenix will present poster A-003 “Clinical validation of the ReEBOV Antigen Rapid Test Kit for the point of care detection of Ebola Virus Disease.”
On July 29, Corgenix will present two posters during the Infectious Disease session: poster B-074 “Analytical validation of the ReEBOV Antigen Rapid Test Kit for the point of care detection of Ebola Virus Disease;” and poster B-072 “Preliminary validation of saliva samples as clinical matrix on the ReEBOV Antigen Rapid Test Kit for the point of care detection of Ebola Virus Disease.”
The Corgenix ReEBOV Ebola rapid test was the first RDT and the first immunoassay authorized for emergency use by the FDA for the presumptive detection of Ebola virus. In February 2015, it was also listed as eligible for procurement by the World Health Organization in the fight against the West Africa Ebola outbreak."
Hey Zag...you forgot to say Ebola, Ebola, Ebola......3 times quickly.
Pronucleotein Biotechnologies has a Patent Transfer and Management Agreement for Field of Use related to foodborne pathogens, food related bacteria, and contaminants and substances related to food analysis, provided by affiliate OTC Biotechnologies.
U.S. Patent No. 7,906,280, entitled “Methods of Producing Intrachain Fluorophore-Quencher FRET-Aptamers and Assays”, issued March 15, 2011.
U.S. Patent Application, Serial No. 12/378,515, entitled “Methods of Producing Homogeneous Plastic-Adherent Aptamer-Magnetic Bead-Fluorophore and Other Sandwich Assays”, filed February 17, 2009.
International Patent Application PCT/IB09/00290, entitled “Methods for Producing Homogenous Plastic-Adherent Aptamer-Magnetic Bead-Fluorophore and Other Sandwich Assays”, filed February 18, 2009, and all corresponding national patent application filings based thereon.
U.S. Patent Application, Serial No. 13/136,820, entitled “Methods and Compositions of Nucleic Acid Ligands for Detection of Foodborne and Waterborne Pathogens”, filed August 11, 2011.
U.S. Patent Application Serial No. 11/433,283, entitled “Methods of Producing Competitive Aptamer FRET Reagents and Assays”, filed May 12, 2006.
U.S. Patent No. 7,910,297, entitled “Therapeutic Nucleic Acid-3’ Conjugates”, issued March 22, 2012.
Over 1,000 aptamer sequences have been claimed by the company in Continuations-in-Part (CIP) of the above Patent Applications. "
Read up WIZ, and see if you can comprehend.
"The Pronucleotein, Inc. team’s runner-up winning submission features a portable device for rapid pathogen screening using DNA aptamer-magnetic bead sandwich assays. It promises a total assay processing and analysis time of about 30 minutes. Dr. John Bruno, VP and CTO of Pronucleotein, Inc. heads the team and is joined by James Byron, CEO of Xgenex. During the Field Accelerator, the Pronucleotein, Inc. team focused on seeing how they could ease the burden of FDA inspectors at ports through rapid screening of suspect foods.
Reflecting on how the Challenge impacted the Pronucleotein team and its future, Dr. Bruno said, “Pronucleotein learned much new information during the Challenge about how the FDA food safety testing procedures function and how they are currently implemented. That information will help to guide our future business plans. In addition, the prize money will enable us to seek AOAC certification for our existing assays and facilitate market entry.”
The prize money was $100,000...and they turn around and use it to seek AOAC certification.
"The U.S. Food and Drug Administration announced the winners of the 2014 FDA Food Safety Challenge, a prize competition to advance breakthrough ideas on how to find disease-causing organisms in food – especially Salmonella in fresh produce.
The key objective of the FDA challenge was to explore the acceleration/elimination of sample preparation and/or enrichment in the testing process, and/or techniques that employ novel or revolutionary techniques to achieve pathogen detection.
Ist Prize went to Purdue University: “Physical method for concentrating Salmonella to detectable levels using automated microfiltration”. This innovation uses miniscule filters to capture small numbers of foodborne pathogens in large volumes of liquid suspensions.
2nd Prize went to Pronucleotein Inc.: “DNA aptamer-magnetic bead sandwich assays used to detect foodborne pathogens with a handheld fluorescence reader”.This innovation uses small strands of DNA bound to magnets to capture foodborne pathogens, which are then tagged with pigments that can light up and be detected."
How about that...aptamer-magnetic bead sandwich assays and miniscule filters.